Literature DB >> 17937990

SAR of a series of anti-HSV-1 acridone derivatives, and a rational acridone-based design of a new anti-HSV-1 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridine series.

Alice M R Bernardino1, Helena C Castro, Izabel C P P Frugulhetti, Natália I V Loureiro, Alexandre R Azevedo, Luiz C S Pinheiro, Thiago M L Souza, Viveca Giongo, Fabiana Passamani, Uiaran O Magalhães, Magaly G Albuquerque, Lúcio M Cabral, Carlos R Rodrigues.   

Abstract

Herpes Simplex Virus (HSV) infections are among the most common human diseases. In this work, we assess the structural features and electronic properties of a series of ten 1-hydroxyacridone derivatives (1a-j) recently described as a new class of non-nucleoside inhibitors of Herpes Simplex Virus-1 (HSV-1). Based on these molecules, we applied rigid analogue and isosteric replacement approaches to design and synthesize nine new 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridine derivatives (2a-i). The biological and computational results of these new molecules were compared with 1-hydroxyacridones. An inhibitory profile was observed in 10-Cl substituted 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridine derivative (2f), which presents the same substituent at the analogous position of 1-hydroxyacridone derivative (1b). The structure-activity relationship (SAR) studies pointed out the 10-position next to nitrogen atom as important for the anti-HSV-1 profile in the pyrazolo-naphthyridine derivatives tested, which reinforced the promising profile for further experimental investigation. The most potent acridone and pyrazolo-naphthridine derivatives were also submitted to an in silico ADMET screening in order to determine their overall drug-score, which confirmed their potential antiviral profile.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937990     DOI: 10.1016/j.bmc.2007.09.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Oxoquinoline derivatives: identification and structure-activity relationship (SAR) analysis of new anti-HSV-1 agents.

Authors:  Paula A Abreu; Viveca A G G da Silva; Fernanda C Santos; Helena C Castro; Cecília S Riscado; Mariana T de Souza; Camilly P Ribeiro; Juliana E Barbosa; Cláudio C C dos Santos; Carlos R Rodrigues; Viviane Lione; Bianca A M Correa; Anna C Cunha; Vitor F Ferreira; Maria C B V de Souza; Izabel C N P Paixão
Journal:  Curr Microbiol       Date:  2011-01-12       Impact factor: 2.188

Review 2.  Synthesis and Anticancer Properties of Functionalized 1,6-Naphthyridines.

Authors:  Mallu Lavanya; Chong Lin; Jincheng Mao; Dhakshanamurthy Thirumalai; Sreenath Reddy Aabaka; Xiaojiang Yang; Jinhua Mao; Zhiyu Huang; Jinzhou Zhao
Journal:  Top Curr Chem (Cham)       Date:  2021-02-24

3.  Identification of a potential lead structure for designing new antimicrobials to treat infections caused by Staphylococcus epidermidis-resistant strains.

Authors:  Luiz C S Pinheiro; Paula A Abreu; Ilidio F Afonso; Bruno Leal; Luiz C D Corrêa; Júlio C Borges; Isakelly P Marques; André L Lourenço; Plinio Sathler; Andre L dos Santos; Cid A Medeiros; Lúcio M Cabral; Maurício L O Júnior; Gilberto A Romeiro; Vitor F Ferreira; Carlos R Rodrigues; Helena C Castro; Alice M R Bernardino
Journal:  Curr Microbiol       Date:  2008-09-23       Impact factor: 2.188

4.  Synthesis and anti-HSV-1 evaluation of new 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridines and 3H-pyrido[2,3-b]pyrazolo[3,4-h]-1,6-naphthyridines.

Authors:  Alice Mr Bernardino; Alexandre R Azevedo; Luiz Cs Pinheiro; Júlio C Borges; Izabel Cp Paixão; Milene Mesquita; Thiago Ml Souza; Maurício S Dos Santos
Journal:  Org Med Chem Lett       Date:  2012-02-01

Review 5.  Anticancer Alkaloids from Trees: Development into Drugs.

Authors:  Tasiu Isah
Journal:  Pharmacogn Rev       Date:  2016 Jul-Dec

6.  De novo transcriptome analysis of Justicia adhatoda reveals candidate genes involved in major biosynthetic pathway.

Authors:  Deepthi Padmanabhan; Adil Lateef; Purushothaman Natarajan; Senthilkumar Palanisamy
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.